The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and Aurora kinases.
CG-806
FLT3
Multi-kinase inhibitor
acute myeloid leukemia
Journal
Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035
Informations de publication
Date de publication:
22 Feb 2023
22 Feb 2023
Historique:
pubmed:
4
3
2023
medline:
4
3
2023
entrez:
3
3
2023
Statut:
epublish
Résumé
Despite the development of several FLT3 inhibitors that have improved outcomes in patients with FLT3-mutant acute myeloid leukemias (AML), drug resistance is frequently observed, which may be associated with the activation of additional pro-survival pathways such as those regulated by BTK, aurora kinases, and potentially others in addition to acquired tyrosine kinase domains (TKD) mutations of To evaluate the anti-leukemia efficacy of the novel multi-kinase inhibitor CG-806, which targets FLT3 and other kinases, in order to circumvent drug resistance and target The anti-leukemia activity of CG-806 was investigated by measuring apoptosis induction and analyzing cell cycle with flow cytometry CG-806 demonstrated superior anti-leukemia efficacy compared to commercially available FLT3 inhibitors, both The results of this study suggest that CG-806 is a promising multi-kinase inhibitor with anti-leukemia efficacy, regardless of
Sections du résumé
Background
UNASSIGNED
Despite the development of several FLT3 inhibitors that have improved outcomes in patients with FLT3-mutant acute myeloid leukemias (AML), drug resistance is frequently observed, which may be associated with the activation of additional pro-survival pathways such as those regulated by BTK, aurora kinases, and potentially others in addition to acquired tyrosine kinase domains (TKD) mutations of
Objective
UNASSIGNED
To evaluate the anti-leukemia efficacy of the novel multi-kinase inhibitor CG-806, which targets FLT3 and other kinases, in order to circumvent drug resistance and target
Methods
UNASSIGNED
The anti-leukemia activity of CG-806 was investigated by measuring apoptosis induction and analyzing cell cycle with flow cytometry
Results
UNASSIGNED
CG-806 demonstrated superior anti-leukemia efficacy compared to commercially available FLT3 inhibitors, both
Conclusion
UNASSIGNED
The results of this study suggest that CG-806 is a promising multi-kinase inhibitor with anti-leukemia efficacy, regardless of
Identifiants
pubmed: 36865133
doi: 10.21203/rs.3.rs-2570204/v1
pmc: PMC9980215
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT04477291']
Types de publication
Preprint
Langues
eng
Déclaration de conflit d'intérêts
Disclosure of Conflicts of Interest: H.Z. and W.R. are employees of Aptose Biosciences; M.A. serves on the Aptose Biosciences Scientific Advisory Board.